DGAP-Adhoc: Cytos Biotechnology Ltd reports the financial results of the First Half Year 2014
Cytos Biotechnology AG / Key word(s): Half Year Results
30.09.2014 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR
---------------------------------------------------------------------------
Schlieren (Zurich), Switzerland, September 30, 2014 - Cytos Biotechnology
Ltd. (SIX:CYTN) ("Cytos" or the "Company") announced today its financial
results for the first half year ended June 30, 2014.
Financial Results
Six-month period from January 1 to June 30, 2014
Funds available for financing the Company's operations amount to CHF 18.69
million as per June 30, 2014, and include cash and cash equivalents,
financial assets and trade and other receivables. This is CHF 21.31 million
lower than on December 31, 2013 (CHF 40.00 million). Cash decreased
primarily due to expenses incurred from ongoing operating activities (CHF
13.71 million) as well as funds spent on wind-down agreements with
suppliers (CHF 5.60 million). In addition, as a result of a settlement
agreement, a payment of CHF 2.00 million was made in the second quarter of
2014. On June 30, 2014, the nominal value of convertible bonds not held by
the Company amounted to CHF 13.17 million. Cytos did not buy back any
convertible bonds on the market during the first half year of 2014.
Revenue comprising deferred income from license fees paid by Novartis of
CHF 0.50 million has been recognized in the first six month of 2014,
unchanged from the same period in 2013.
Financial summary (IFRS, consolidated)
(in CHF million) HY 2014 HY 2013
Revenue 0.5 0.5
Net operating costs (16.5) (10.5)
Operating loss (16.0) (10.0)
Net loss (23.4) (13.6)
Net loss per share (in CHF) (0.77) (0.61)
(in CHF million) 30.6.2014 31.12.20
13
Cash, cash equivalents & trade and other 18.7 40.0
receivables
Full-time equivalents 28.2 28.7
The detailed First Half Year Financial Report 2014 can be downloaded at:
http://www.cytos.com/uploads/2014/Cytos_HY_1_2014_EN.pdf
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.
Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.
www.cytos.com
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=TAFKSMTJHO
Document title: Cytos_HY1_2014_EN
30.09.2014 News transmitted by EQS Schweiz AG.
The issuer is responsible for the contents of the release.
EQS publishes regulatory releases, media releases on the capital
market and press releases.
The EquityStory Group distributes authentic and real-time financial news
for over 1'300 listed companies.
The Swiss news archive can be found at www.equitystory.ch/news
---------------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Valor: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Frankfurt in Open Market ; SIX
End of Announcement EQS Group News-Service
---------------------------------------------------------------------------